{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=64",
    "query": {
      "intervention": "cohort 4",
      "page": 64
    },
    "page_size": 10
  },
  "pagination": {
    "page": 64,
    "page_size": 10,
    "total_count": 3785,
    "total_pages": 379,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=65&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=63&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T23:31:07.818Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02778386",
      "title": "Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Toxicity"
      ],
      "interventions": [
        {
          "name": "N-Methanocarbathymidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo Capsule",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "N&N Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 28,
      "start_date": "2016-04",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2016-09-22",
      "last_synced_at": "2026-11-19T23:31:07.818Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02778386"
    },
    {
      "nct_id": "NCT04126070",
      "title": "Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone Sensitive Prostate Cancer",
        "Prostate Adenocarcinoma",
        "Metastasis Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Androgen Deprivation Therapy",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xiao X. Wei, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 47,
      "start_date": "2020-05-11",
      "completion_date": "2026-10-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-11-19T23:31:07.818Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04126070"
    },
    {
      "nct_id": "NCT07905677",
      "title": "Phase 1 Study of VT-101 in Advanced Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "VT-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael J. Goodheart",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 99 Years · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2026-10-26",
      "completion_date": "2030-10-23",
      "has_results": false,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-19T23:31:07.818Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07905677"
    },
    {
      "nct_id": "NCT04587609",
      "title": "Reducing Cell Phone Use While Driving Among High Risk UBI Auto Policy Holders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Distracted Driving",
        "Driving Impaired"
      ],
      "interventions": [
        {
          "name": "Free Phone Mounts",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Commitment Contract",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Personalized Habit Tips",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Social Gamification Feedback",
          "type": "BEHAVIORAL"
        },
        {
          "name": "\"Contest\" Financial Incentives",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1668,
      "start_date": "2021-03-01",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-07-02",
      "last_synced_at": "2026-11-19T23:31:07.818Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04587609"
    },
    {
      "nct_id": "NCT00138177",
      "title": "Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Colon Cancer",
        "Recurrent Rectal Cancer",
        "Stage III Colon Cancer",
        "Stage III Rectal Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Rectal Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2005-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-30",
      "last_synced_at": "2026-11-19T23:31:07.818Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00138177"
    },
    {
      "nct_id": "NCT02206100",
      "title": "PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PER977",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2014-04",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2020-05-21",
      "last_synced_at": "2026-11-19T23:31:07.818Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02206100"
    },
    {
      "nct_id": "NCT03921528",
      "title": "An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinal Muscular Atrophy",
        "Spinal Muscular Atrophy Type 3",
        "Spinal Muscular Atrophy Type 2",
        "SMA",
        "Neuromuscular Diseases",
        "Muscular Atrophy",
        "Atrophy",
        "Muscular Atrophy, Spinal",
        "Neuromuscular Manifestations"
      ],
      "interventions": [
        {
          "name": "SRK-015",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Scholar Rock, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 58,
      "start_date": "2019-04-22",
      "completion_date": "2024-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-12-02",
      "last_synced_at": "2026-11-19T23:31:07.818Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03921528"
    },
    {
      "nct_id": "NCT06465199",
      "title": "Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Atypical Teratoid/Rhabdoid Tumor",
        "Embryonal Tumor With Multilayered Rosettes",
        "Ewing Sarcoma",
        "Diffuse Intrinsic Pontine Glioma",
        "Osteosarcoma",
        "Neuroblastoma",
        "DIPG Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Eflornithine (DFMO)",
          "type": "DRUG"
        },
        {
          "name": "AMXT 1501 Dicaprate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "Up to 26 Years"
      },
      "enrollment_count": 265,
      "start_date": "2026-05-13",
      "completion_date": "2035-05",
      "has_results": false,
      "last_update_posted_date": "2026-11-19",
      "last_synced_at": "2026-11-19T23:31:07.818Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06465199"
    },
    {
      "nct_id": "NCT04141644",
      "title": "Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2020-08-20",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-11-19T23:31:07.818Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04141644"
    },
    {
      "nct_id": "NCT05369832",
      "title": "An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 139,
      "start_date": "2022-12-16",
      "completion_date": "2025-04-11",
      "has_results": true,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-11-19T23:31:07.818Z",
      "location_count": 85,
      "location_summary": "Dothan, Alabama • Chandler, Arizona • Gilbert, Arizona + 63 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05369832"
    }
  ]
}